Mirabegron Dosage
Medically reviewed by Drugs.com. Last updated on Mar 26, 2024.
Applies to the following strengths: 25 mg; 50 mg; 8 mg/mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Urinary Incontinence
Monotherapy:
Initial dose: 25 mg orally once a day
Maintenance dose: 25 to 50 mg orally once a day based on individual patient efficacy and tolerability
Combination therapy with solifenacin (muscarinic antagonist)
Initial dose: 25 mg orally once a day plus solifenacin 5 mg orally once a day
- After 4 to 8 weeks, may increase mirabegron to 50 mg per day based on individual patient efficacy and tolerability
Comments:
- Adults dosage for the granules has not been determined.
- The tablet and the granules formulation are not substitutable on a milligram-per-milligram basis.
- In clinical trials, mirabegron 25 mg was effective within 8 weeks, while the 50 mg dose showed efficacy within 4 weeks.
- In a clinical trial with combination mirabegron and solifenacin, combination therapy demonstrated greater improvements from baseline compared either drug alone; improvements were demonstrated at 3 months and maintained throughout the 1-year trial.
Uses: As monotherapy or in combination with a muscarinic antagonist (solifenacin) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
Usual Adult Dose for Urinary Frequency
Monotherapy:
Initial dose: 25 mg orally once a day
Maintenance dose: 25 to 50 mg orally once a day based on individual patient efficacy and tolerability
Combination therapy with solifenacin (muscarinic antagonist)
Initial dose: 25 mg orally once a day plus solifenacin 5 mg orally once a day
- After 4 to 8 weeks, may increase mirabegron to 50 mg per day based on individual patient efficacy and tolerability
Comments:
- Adults dosage for the granules has not been determined.
- The tablet and the granules formulation are not substitutable on a milligram-per-milligram basis.
- In clinical trials, mirabegron 25 mg was effective within 8 weeks, while the 50 mg dose showed efficacy within 4 weeks.
- In a clinical trial with combination mirabegron and solifenacin, combination therapy demonstrated greater improvements from baseline compared either drug alone; improvements were demonstrated at 3 months and maintained throughout the 1-year trial.
Uses: As monotherapy or in combination with a muscarinic antagonist (solifenacin) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
Usual Adult Dose for Overactive Bladder Syndrome
Monotherapy:
Initial dose: 25 mg orally once a day
Maintenance dose: 25 to 50 mg orally once a day based on individual patient efficacy and tolerability
Combination therapy with solifenacin (muscarinic antagonist)
Initial dose: 25 mg orally once a day plus solifenacin 5 mg orally once a day
- After 4 to 8 weeks, may increase mirabegron to 50 mg per day based on individual patient efficacy and tolerability
Comments:
- Adults dosage for the granules has not been determined.
- The tablet and the granules formulation are not substitutable on a milligram-per-milligram basis.
- In clinical trials, mirabegron 25 mg was effective within 8 weeks, while the 50 mg dose showed efficacy within 4 weeks.
- In a clinical trial with combination mirabegron and solifenacin, combination therapy demonstrated greater improvements from baseline compared either drug alone; improvements were demonstrated at 3 months and maintained throughout the 1-year trial.
Uses: As monotherapy or in combination with a muscarinic antagonist (solifenacin) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
Usual Pediatric Dose for Bladder Muscle Dysfunction - Overactive
Pediatric Patients weighing less than 35 kg (Granules):
Starting Dose:
- For 11 kg to less than 22 kg: 3 mL (24 mg)
- Maximum Dose: 6 mL (48 mg)
- For 22 kg to less than 35 kg: 4 mL (32 mg)
- Maximum Dose: 8 mL (64 mg)
Pediatric Patients weighing 35 kg or more (Tablets or Granules):
Tablets:
Initial dose: 25 mg orally once a day
Maintenance dose: After 4 to 8 weeks, may increase to 50 mg orally once a day based on individual patient efficacy and tolerability
Granules:
Initial dose: 6 mL (48 mg) orally once
Maintenance dose: After 4 to 8 weeks, may increase to 10 mL (80 mg) orally once a day based on individual patient efficacy and tolerability
Comments:
- The granules recommended dosages are determined based on patients' weight.
- The tablet and the granules formulations are not substitutable on a milligram-per-milligram basis.
- Do not combine the tablets with the granules to achieve the total dose.
- It is recommended to assess patients periodically for potential dosage adjustment.
Use:
- Tablets: For the treatment of neurogenic detrusor overactivity in pediatric patients aged 3 years and older and weighing 35 kg or more
- Granules: For the treatment of neurogenic detrusor overactivity in pediatric patients aged 3 years and older
Renal Dose Adjustments
Adults:
- Mild or moderate renal dysfunction [Estimated glomerular filtration rate (eGFR) 30 to 89 mL/min/1.73 m2]: No adjustment recommended
- Severe renal dysfunction (eGFR 15 to 29 mL/min/1.73 m2): 25 mg orally once a day
- End-Stage renal dysfunction (eGFR less than 15 mL/min/1.73 m2 or undergoing hemodialysis): Not recommended
Pediatrics:
Pediatric Patients Aged 3 Years or Older Weighing Less Than 35 kg:
- Mild or moderate renal dysfunction (eGFR 30 to 89 mL/min/1.73 m2): No adjustment recommended
- Severe renal dysfunction (eGFR 15 to 29 mL/min/1.73 m2):
22 kg to less than 35 kg 4 mL (32 mg): 4 mL (32 mg) orally once a day
- End-Stage renal dysfunction (eGFR less than 15 mL/min/1.73 m2 or undergoing hemodialysis): Not recommended
Pediatric Patients Aged 3 Years or Older Weighing 35 kg or more:
Tablets:
- Mild or moderate renal dysfunction (eGFR 30 to 89 mL/min/1.73 m2): No adjustment recommended
- Severe renal dysfunction (eGFR 15 to 29 mL/min/1.73 m2): 25 mg orally once a day
- End-Stage renal dysfunction (eGFR less than 15 mL/min/1.73 m2 or undergoing hemodialysis): Not recommended
Granules:
- Mild or moderate renal dysfunction (eGFR 30 to 89 mL/min/1.73 m2): No adjustment recommended
- Severe renal dysfunction (eGFR 15 to 29 mL/min/1.73 m2): 6 mL (48 mg) orally once a day
- End-Stage renal dysfunction (eGFR less than 15 mL/min/1.73 m2 or undergoing hemodialysis): Not recommended
Liver Dose Adjustments
Adults:
- Mild liver dysfunction (Child-Pugh A): No adjustment recommended
- Moderate liver dysfunction (Child-Pugh B): 25 mg orally once a day
- Severe liver dysfunction (Child-Pugh C): Not recommended
Pediatrics:
Pediatric Patients Aged 3 Years or Older Weighing Less Than 35 kg:
- Mild liver dysfunction (Child-Pugh A): No adjustment recommended
- Moderate liver dysfunction (Child-Pugh B):
22 kg to less than 35 kg 4 mL (32 mg): 4 mL (32 mg) orally once a day
- Severe liver dysfunction (Child-Pugh C): Not recommended
Pediatric Patients Aged 3 Years or Older Weighing 35 kg or more:
Tablets:
- Mild liver dysfunction (Child-Pugh A): No adjustment recommended
- Moderate liver dysfunction (Child-Pugh B): 25 mg orally once a day
- Severe liver dysfunction (Child-Pugh C): Not recommended
Granules:
- Mild liver dysfunction (Child-Pugh A): No adjustment recommended
- Moderate liver dysfunction (Child-Pugh B): 6 mL (48 mg)
- Severe liver dysfunction (Child-Pugh C): Not recommended
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to the active substance or any product excipients
Safety and efficacy have not been established in patients younger than 3 years.
Consult WARNINGS section for additional precautions.
Dialysis
Hemodialysis: Not recommended
Peritoneal dialysis: Data not available
Other Comments
Administration advice:
- Adults may take the tablets orally with or without food and swallow whole with water; do not chew, divide, or crush
- Pediatric patients should take the tablets and reconstituted granules formulation with food to reduce potential exposure-related risks, such as increased heart rate
- Pediatrics patients should take the reconstituted granules formulation within 1 hour after preparation and not save the dose for later
- Shake the reconstituted granules formulation for 1 minute each day if the suspension is not used for 2 or more days
- When the suspension is ready to use, shake the bottle vigorously for 1 minute then let it stand until the foam on top of the suspension is gone (approximately 1 to 2 minutes)
- If you miss a dose, take the missed dose as soon as possible. Skip that dose if more than 12 hours have passed and resume with the next scheduled dose; do not take 2 doses on the same day
Storage requirements:
- Tablets: 20°C to 25°C (68°F to 77°F); excursions 15°C to 30°C (59°F to 86°F)
- Granules: 20°C to 25°C (68°F to 77°F); excursions 15°C to 30°C (59°F to 86°F)
- Reconstituted suspension: 20°C to 25°C (68°F to 77°F) for up to 28 days. Discard unused portion after 28 days
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
Monitor:
- Periodic blood pressure measurements, especially in patients with hypertension
- Monitor for urinary retention
- Monitor for angioedema
Patient advice:
- Read the US approved Patient Information.
- Patients should be advised to contact their healthcare provider if they have a high blood pressure reading if they are unable to empty their bladder or experiencing angioedema.
- Pediatric patients and/or their caregivers should be advised to use an appropriate measuring device for measuring the correct dose.
- Pediatrics patients should take the reconstituted granules formulation within 1 hour after preparation and not save the dose for later.
- Shake the reconstituted granules formulation for 1 minute each day if the suspension is not used for 2 or more days
- When the suspension is ready to use, shake the bottle vigorously for 1 minute then let it stand until the foam on top of the suspension is gone (approximately 1 to 2 minutes)
- If you miss a dose, take the missed dose as soon as possible. Skip that dose if more than 12 hours have passed and resume with the next scheduled dose; do not take 2 doses on the same day
More about mirabegron
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (352)
- Drug images
- Side effects
- During pregnancy
- Drug class: urinary antispasmodics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.